dr megan carter glp 1 M.D. - Physician GLP-1s are everywhere, and so

New approaches, from microneedle transdermal patches to implantable slow-release systems, are being engineered to deliver GLP-1R agonists steadily over time. Additionally, these types of devices may have reduced injection frequency, which improves adherence, and with easier drug delivery systems, theres a smaller learning curve, which also increases patient compliance, she adds

2006 Jun 30;126-127:250-257

GLP-1 receptor agonists are typically initiated at a low dose and gradually increased over several weeks to minimise side effects

Wyse is the visionary behind the International Linked Clinical Trials (LCT) program, which aims to prioritize potential disease-modifying compounds for Parkinsons treatment

So when in that space its like, wait a second

My prescription was approved the next day